http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20010014331-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-49 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C243-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C243-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C- |
| filingDate | 1998-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20010014331-A |
| titleOfInvention | Hydrazine derivatives |
| abstract | The hydrazine derivatives of formula (I), or pharmaceutically acceptable salts thereof, inhibit the release of tumor necrosis factor (TNF-a) and transforming growth factor (TGF-a) from cells as well as keratinocyte proliferation :n n n Formula In n n n n n n n In this formula,n n n Y signifies CO or SO 2 ;n n n R 1 means lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl;n n n R 2 means lower alkyl, halo-lower alkyl, aryl-lower alkyl, aryl-lower alkenyl or aryl when Y signifies SO 2 and lower alkyl, halo-lower alkyl, lower alkoxy, lower alkoxycarbonyl, acyl, lower cycloalkyl, aryl, aryl-lower alkyl, aryl-represents lower alkoxy or NR 5 R 6, and;n n n R 3 is hydrogen,n n n Lower alkyl substituted or unsubstituted with cyano, amino, hydroxy, lower alkoxy, lower alkoxycarbonyl, heterocyclyl or heterocyclylcarbonyl,n n n Lower alkenyl, lower alkynyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl-lower alkyl, aryl-lower alkenyl, aryl or heterocyclyl; orn n n R 2 and R 3 together form a moiety of a 5-, 6- or 7-membered cyclic amide, cyclic imide, cyclic sulfonamide or cyclic urethane group;n n n R 4 is lower alkyl, hydroxy-lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or aryl formula X-, X- heteroaryl or - (CH 2) 1-2 -CH = CR 7 > R < 8 & gt ;;n n n X represents a spacer group;n n n R 5 and R 6 are each independently hydrogen, lower alkyl or aryl-lower alkyl;n n n R 7 and R 8 together represent a lower alkylene group in which one methylene group is substituted or unsubstituted by a hetero atom.n n n They are particularly useful as medicaments for the treatment of inflammation, fever, hemorrhage, sepsis, rheumatoid arthritis, osteoarthritis, multiple sclerosis or psoriasis. |
| priorityDate | 1997-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 519.